Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 6/20 | 0.49 |
| ▸ | NAAA | Q02083 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ALPL | P05186 | 1/20 | 0.42 |
| ▸ | ALPI | P09923 | 1/20 | 0.42 |
| ▸ | USP19 | O94966 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14312427 | 0.84 | NPY5R (0.45) | NPY5RNAAANPC1RAB9AKDR | |
| SCHEMBL6584530 | 0.77 | NPY5R (0.72) | NPY5RNPC1RAB9AKDRRET | |
| SCHEMBL2469435 | 0.75 | NAAA (0.52) | NAAANPC1TDP1USP19FKBP1A | |
| SCHEMBL13688315 | 0.75 | CHRM5 (0.60) | NAAANPC1TDP1FKBP1ATSHR | |
| SCHEMBL2700497 | 0.74 | NPC1 (0.63) | NAAANPC1TDP1MAPTFKBP1A | |
| SCHEMBL2471495 | 0.74 | ALDH1A1 (0.58) | NAAANPC1TDP1FKBP1A | |
| SCHEMBL2469100 | 0.73 | MAPT (0.50) | NAAARAB9AUSP19MAPT | |
| SCHEMBL13183012 | 0.73 | NAAA (0.48) | NAAANPC1TDP1FKBP1ATSHR | |
| SCHEMBL13593925 | 0.72 | NPC1 (0.60) | NAAANPC1TDP1MAPTFKBP1A | |
| SCHEMBL2469930 | 0.72 | GRIN2B (0.53) | NAAANPC1TDP1FKBP1ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2371366-A1 | Heterocyclo inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-17 | — | — | US | disclosed |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-17 | — | — | US | disclosed |
| US-7582654-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582654-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNH2, KCNQ5 | NPY5R 1362/4885NAAA 3237/4885NPC1 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.